Ferring and Rebiotix claim a first in microbiome therapy, as RBX2660 hits the market in a phase 3 C. diff trial, setting up filing talks with the FDA ...

The US Food and Drug Administration (FDA) has approved Swiss drugmaker Ferring Pharmaceuticals’ Adstiladrin (nadofaragene firedenovec-vncg) for the treatment of adult patients with high-risk ...